Human Serum Albumin USP 25% Solution
A sterile solution of human serum albumin at 25% concentration, prepared from human plasma for therapeutic use in treating hypovolemia and shock. It falls under HTS 3002.90.52.50 as a blood fraction prepared for therapeutic use, derived from human blood through fractionation processes. This immunological product supports plasma volume expansion in clinical settings.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If unprocessed or minimally prepared whole blood
Unmodified human blood for transfusion falls under 3001 as human blood, not processed fractions.
If not prepared for therapeutic, prophylactic, or diagnostic uses
Unmodified blood albumin without therapeutic preparation is classified as industrial albumin in Chapter 35.
If specifically classified as antisera or other blood fractions in subheadings
Certain defined blood fractions like immunoglobulins may shift to more specific subheadings within 3002.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Obtain FDA biologics license and ensure cold chain documentation for plasma-derived products to maintain sterility
• Provide certificates of analysis verifying viral inactivation processes to comply with blood safety regulations
• Avoid misclassification by confirming it's not unmodified blood albumin under heading 3502
Related Products under HTS 3002.90.52.50
IVIG Intravenous Immunoglobulin 10% Infusion
A pooled immunoglobulin G preparation from human plasma, used therapeutically for primary immunodeficiency and autoimmune disorders. Classified under HTS 3002.90.52.50 as an immunological product and blood fraction obtained via biotechnological purification. It modulates immune responses in patients with antibody deficiencies.
Monoclonal Antibody Infliximab Biosimilar
A recombinant chimeric monoclonal antibody targeting TNF-alpha, used for treating inflammatory conditions like rheumatoid arthritis. It qualifies under HTS 3002.90.52.50 as an immunological product directly involved in immune regulation, produced via biotechnological processes. Administered intravenously for therapeutic purposes.
Interferon Beta-1a Injection for MS
A recombinant interferon beta-1a formulation for relapsing multiple sclerosis treatment, regulating immune processes. Falls under HTS 3002.90.52.50 as an immunological product (interferon) prepared for therapeutic use via biotechnological methods. It reduces disease activity in neurological conditions.
Recombinant Human Erythropoietin Alfa
A biotechnologically produced hematopoietin stimulating red blood cell production, used in anemia treatment for chronic kidney disease patients. Classified in HTS 3002.90.52.50 as an immunological product (hematopoietin) for therapeutic use. It is a growth factor directly involved in blood cell regulation.
Anti-Hemophilic Factor VIII Concentrate
A plasma-derived or recombinant Factor VIII concentrate for preventing bleeding in hemophilia A patients. It is a blood fraction and immunological product under HTS 3002.90.52.50, prepared for therapeutic prophylactic use. Essential for clotting factor replacement therapy.
Botulinum Toxin Type A for Therapeutic Use
Purified botulinum toxin type A complex, indicated for cervical dystonia and spasticity management. Falls under HTS 3002.90.52.50 as a toxin prepared for therapeutic use, a culture-derived product modulating neuromuscular transmission. Used in measured doses for neurological conditions.